{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:06:39Z","timestamp":1785182799590,"version":"3.55.0"},"reference-count":25,"publisher":"American Chemical Society (ACS)","issue":"23","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100013806","name":"Shenyang Pharmaceutical University","doi-asserted-by":"publisher","award":["ZQ202301"],"award-info":[{"award-number":["ZQ202301"]}],"id":[{"id":"10.13039\/501100013806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22177080"],"award-info":[{"award-number":["22177080"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Liaoning Province for Excellent Young Scholars","award":["2023JH3\/10200015"],"award-info":[{"award-number":["2023JH3\/10200015"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gout is one of the most common inflammatory arthritic diseases. Clinically, the need for safer and more effective xanthine oxidase (XO) inhibitors remains unmet. Here, a novel series of isoidide subunit-containing XO inhibitors was developed through structural optimization of febuxostat. Compounds Z23\u2013Z26 and Z28\u2013Z30 exhibited potent in vitro XO inhibitory activity, with IC50 values ranging from 0.5 to 2.2 nM. Subsequent assessments of metabolic stability in liver microsomes from multiple species and hypouricemic effects in animal models led to the identification of Z29 as the most promising compound. It exhibited significant XO inhibition and outstanding serum uric acid (SUA)-lowering efficacy in both mouse and rat acute hyperuricemia models. Furthermore, Z29 showed no toxicity to vascular cells in vitro and demonstrated a favorable safety profile in in vivo evaluations of acute toxicity and cardiotoxicity. These findings highlight Z29 as a promising therapeutic candidate for hyperuricemia and gout.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c02404","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:13:17Z","timestamp":1764324797000},"page":"25416-25437","source":"Crossref","is-referenced-by-count":2,"title":["Novel Isoidide\nSubunit-Containing Xanthine Oxidase\nInhibitors with Potent Hypouricemic Effects"],"prefix":"10.1021","volume":"68","author":[{"given":"Xiaoyi","family":"Zeng","sequence":"first","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, PR China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, PR China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, PR China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, PR China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Huang","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, PR China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Meng","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, PR China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Lu","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, PR China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6538-0855","authenticated-orcid":true,"given":"Lihui","family":"Wang","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, PR China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4634-535X","authenticated-orcid":true,"given":"Mingze","family":"Qin","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, PR China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2026072715444957400_cit1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.maturitas.2018.10.012","article-title":"Gout \u2013\nAn update of aetiology, genetics, co-morbidities and management","volume":"118","author":"Robinson","year":"2018","journal-title":"Maturitas"},{"key":"2026072715444957400_cit2","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/HJH.0000000000001980","article-title":"Uric acid\nand hypertension: a focused review and practical recommendations","volume":"37","author":"De Becker","year":"2019","journal-title":"J. Hypertens."},{"key":"2026072715444957400_cit3","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.2174\/138161205774913219","article-title":"Uric acid and the\nkidney: urate transport, stone disease and progressive renal failure","volume":"11","author":"Capasso","year":"2005","journal-title":"Curr. Pharm. Des."},{"issue":"10","key":"2026072715444957400_cit4","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1586\/14779072.2014.957675","article-title":"Hyperuricemia and cardiovascular disease risk","volume":"12","author":"Borghi","year":"2014","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"2026072715444957400_cit5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","article-title":"Impact of comorbidities\non gout and hyperuricaemia:\nan update on prevalence and treatment options","volume":"15","author":"Bardin","year":"2017","journal-title":"BMC Med."},{"issue":"7","key":"2026072715444957400_cit6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/humrep\/det085","article-title":"Serum uric\nacid in relation to endogenous reproductive hormones during the menstrual\ncycle: findings from the BioCycle study","volume":"28","author":"Mumford","year":"2013","journal-title":"Hum.\nReprod."},{"issue":"6","key":"2026072715444957400_cit7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia,\nacute and chronic kidney disease, hypertension, and cardiovascular\ndisease: Report of a Scientific Workshop Organized by the National\nKidney Foundation","volume":"71","author":"Johnson","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"2026072715444957400_cit8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2174\/0929867023371229","article-title":"Progress towards the discovery of\nxanthine oxidase inhibitors","volume":"9","author":"Borges","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"2026072715444957400_cit9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1517\/13543776.2011.577417","article-title":"Xanthine oxidase\ninhibitors: a patent survey","volume":"21","author":"Kumar","year":"2011","journal-title":"Expert Opin. Ther.\nPatents"},{"issue":"7","key":"2026072715444957400_cit10","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/cmdc.201900034","article-title":"Inhibitors of xanthine oxidase: scaffold\ndiversity and structure-based drug design","volume":"14","author":"Luna","year":"2019","journal-title":"ChemMedChem."},{"issue":"6","key":"2026072715444957400_cit11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","article-title":"2020 American\ncollege of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"2026072715444957400_cit12","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101501","article-title":"Allopurinol hypersensitivity:\npathogenesis and prevention","volume":"34","author":"Stamp","year":"2020","journal-title":"Best Pract. Res.,\nClin. Rheumatol."},{"issue":"3","key":"2026072715444957400_cit13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/08860220701861045","article-title":"Allopurinol-induced\nrecurrent DRESS syndrome: Pathophysiology and Treatment","volume":"30","author":"Shalom","year":"2008","journal-title":"Renal Failure"},{"issue":"12","key":"2026072715444957400_cit14","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/jcpt.13740","article-title":"Allopurinol-induced\nStevens-Johnson syndrome and toxic epidermal necrolysis: Signal detection\nand preventability from Vietnam National pharmacovigilance database","volume":"47","author":"Huong","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"issue":"13","key":"2026072715444957400_cit15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular\nsafety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"2026072715444957400_cit16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/jcpt.12392","article-title":"Clinical efficacy\nand safety of topiroxostat in Japanese male hyperuricemic patients\nwith or without gout: an exploratory, phase 2a, multicentre, randomized,\ndouble-blind, placebo-controlled study","volume":"41","author":"Hosoya","year":"2016","journal-title":"J. Clin.\nPharm. Ther."},{"key":"2026072715444957400_cit17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115532","article-title":"Identification\nof 5-[5-cyano-1-(pyridin-2-ylmethyl)-1H-indole-3-carboxamido] thiazole-4-carboxylic\nacid as apromising dual inhibitor of urate transporter 1 and xanthine\noxidase","volume":"257","author":"Lin","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"18","key":"2026072715444957400_cit18","doi-asserted-by":"publisher","first-page":"9434","DOI":"10.1039\/D2FO01533A","article-title":"Anserinebeneficial\neffects in hyperuricemic rats by inhibiting XOD, regulating uric acid\ntransporter and repairing hepatorenal injury","volume":"13","author":"Chen","year":"2022","journal-title":"Food Funct."},{"issue":"9","key":"2026072715444957400_cit19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0291330","article-title":"Human cardiovascular disease model\npredicts xanthine oxidase inhibitor cardiovascular risk","volume":"18","author":"Abdel Moneim","year":"2023","journal-title":"PLoS One"},{"issue":"3","key":"2026072715444957400_cit20","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1074\/jbc.M208307200","article-title":"An Extremely potent inhibitor of\nxanthine oxidoreductase","volume":"278","author":"Okamoto","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"2","key":"2026072715444957400_cit21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1021\/acsmedchemlett.2c00476","article-title":"Incorporation of an isohexide subunit\nimproves the drug-like properties of bioactive compounds","volume":"14","author":"Sidduri","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"2026072715444957400_cit22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.07.062","article-title":"Targeting the subpocket\nin xanthine oxidase: design, synthesis, and\nbiological evaluation of 2-[4-alkoxy-3-(1H-tetrazol-1-yl)\nphenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives","volume":"181","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"2026072715444957400_cit23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114682","article-title":"Discovery of novel benzbromarone\nanalogs with improved pharmacokinetics and benign toxicity profiles\nas antihyperuricemic agents","volume":"242","author":"Zhao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"2026072715444957400_cit24","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.3168\/jds.2023-23369","article-title":"Whey protein peptides\nPEW and LLW synergistically ameliorate hyperuricemia\nand modulate gut microbiota in potassium oxonate and hypoxanthine-induced\nhyperuricemic rats","volume":"106","author":"Qi","year":"2023","journal-title":"J. Dairy Sci."},{"issue":"123","key":"2026072715444957400_cit25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ijbiomac.2018.11.077","article-title":"Anti-hyperuricemic\nand anti-gouty arthritis activities of polysaccharide purified from\nLonicera japonica in model rats","volume":"15","author":"Yang","year":"2019","journal-title":"Int. J. Biol.\nMacromol."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c02404","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/23\/25416\/66289293\/acs.jmedchem.5c02404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/23\/25416\/66289293\/acs.jmedchem.5c02404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:58:11Z","timestamp":1785182291000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/23\/25416\/5234500\/Novel-Isoidide-Subunit-Containing-Xanthine-Oxidase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":25,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,11,28]]},"published-print":{"date-parts":[[2025,12,11]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02404","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}